In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.
Adults aged ≥ 18 years
No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)
Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO
Equipped with an arterial catheter for blood sampling
Minors
Patients under court-appointed guardianship or conservatorship
Pregnant or breastfeeding women
Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia